We studied immune modulation and antioxidant effects of wheat peptides on immunosuppressed mice. Mice were administrated with wheat peptides orally for 10 days and treated with cyclophosphamide at the 8th day. The indexes including serum hemolysin, plaque forming cells, spleen cells proliferation, liver antioxidant enzymes activties, malondialdehyde (MDA), scavenging serum 2,2-Diphenyl-1-picrylhydrazyl and *OH and macrophage phagocytic ability in vitro were measured to assess the immune functions and antioxidation abilities. In vivo study shows that cyclophosphamide significantly decreases serum hemolysin (HC50) and phagocytic function of macrophages. Simultaneously, liver superoxide dismutase, catalase activity and total oxidation capacity were decreased and malondialdehyde was increased. Wheat peptides could recover HC50 and spleen cell proliferation when orally administrated. Furthermore, they could also enhance serum 2,2-Diphenyl-1-picrylhydrazyl and *OH scavenging. In conclusion, wheat peptides can help body resist the stress related disorders in immune and antioxidant system.
Adjuvants, Immunologic ; pharmacology ; Animals ; Antioxidants ; pharmacology ; Immunocompromised Host ; drug effects ; immunology ; Male ; Mice ; Oxidative Stress ; drug effects ; Peptides ; immunology ; pharmacology ; Random Allocation ; Triticum ; chemistry ; immunology

OBJECTIVETo observe the effects of bagasse polysaccharide on the immune functions of immunosuppressed mice.

METHODSImmunosuppressed mouse models were established by intraperitoneal injections with cyclophosphamide followed by daily intragastric administration of bagasse polysaccharide. After the treatments, the mice were examined for immune organ weight index, phagocytotic function of the macrophages, delayed type hypersensitivity, serum IgM level following exposure to chicken red blood cells, formation of hemolytic plaques, T cell percentage and lymphocyte transformation.

RESULTSTreatment of the immunosuppressed mice with bagasse polysaccharide at the daily dose of 200 and 400 mg/kg significantly increased the weight of the immune organs, phagocytotic function of the macrophages, delayed type hypersensitivity, serum IgM level against chicken red blood cells, formation of hemolytic plaques, T cell percentage and lymphocyte transformation.

CONCLUSIONBagasse polysaccharide can enhance the immune functions of immunosuppressed mice.

Animals ; Cellulose ; chemistry ; Cyclophosphamide ; Female ; Immunocompromised Host ; immunology ; Lymphocyte Activation ; drug effects ; Macrophages ; immunology ; Male ; Mice ; Phagocytosis ; drug effects ; Polysaccharides ; pharmacology ; Random Allocation

OBJECTIVE: To explore the immunoregulatory effect of Huangqi Fuzhengtang on immunosuppressive mice. METHODS: The immunosuppressive mouse model was established by using hydrocortisone. Huangqi Fuzhengtang and Yupingfeng San apozema were given to the mice intragastrically. The contents of hemolysin, IL-2, and INF-gamma in the mouse serum and the expression of CD3(+), CD4(+), and CD8(+) in the peripheral blood lymphocytes were measured. RESULTS: Huangqi Fuzhengtang could obviously elevate the contents of hemolysin, IL-2, INF-gamma and the ratio of CD4(+) and CD8+, which was more effective than Yupingfeng San. CONCLUSION Huangqi Fuzhengtang could improve the immune function in the immunosuppressive mice.
Adjuvants, Immunologic ; pharmacology ; Animals ; Astragalus propinquus ; chemistry ; Drugs, Chinese Herbal ; pharmacology ; Hydrocortisone ; Immunocompromised Host ; drug effects ; immunology ; Male ; Mice ; Random Allocation ; T-Lymphocyte Subsets ; drug effects

Adult ; Anti-Bacterial Agents ; therapeutic use ; Humans ; Immunocompromised Host ; Male ; Nocardia ; drug effects ; pathogenicity ; Nocardia Infections ; diagnosis ; drug therapy ; Tetracyclines ; therapeutic use

OBJECTIVETo study the effect of polysaccharides in processed Sibiraea on the immunologic function of immunosuppression mice.

METHODThe immunosuppressed mice were induced by cyclophosphamide. After the treatment, the organ weight index and the delayed type hypersensitivity of the mice were investigated. The humoral immune function was determined by serum hemolysin assay. Non-specific immune function was determined by carbon clearance method. Cellular immune function was determined by spleen lymphocyte proliferation test. Two hundred kunming mice were randomly divided into five groups: normal controls, model group, low-dose group (110 mg x kg(-1)), middle-dose group (220 mg x kg(-1)), high-dose group (440 mg x kg(-1)). Drugs were given to the mice by oral gavage every day.

RESULTThe immunosuppressed mice treated with Sibiraea polysibcharide at intragastrica dose of 110-440 mg x kg(-1) have increased weight of the immune organs, increased content of DTH and content in serum hemolysin lgG and lgM. Mean while the rate of carbon clearance was enhanced and the proliferation of spleen lymphocyte was increased.

CONCLUSIONPolysaccharides in processed Sibiraea can increase the weight of the immune organs. At the same time, non-specific immune, DTH, humoral immune and cellular immune function were enhanced significantly.

Animals ; Disease Models, Animal ; Female ; Humans ; Immunity ; drug effects ; Immunocompromised Host ; drug effects ; Male ; Mice ; Organ Size ; drug effects ; Polysaccharides ; administration & dosage ; Random Allocation ; Rosaceae ; chemistry ; Spleen ; drug effects ; immunology

To compare the effects of polysaccharide nucleic acid fraction of bacillus calmette guerin (BCG-PSN) and thymopeptides on T-lymphocytes of normal and immunosuppressed mice, CD4+ and CD8+ T-lymphocyte subsets of single nucleic cell in thymus, spleen and peripheral blood were detected successively by flow cytometry after application of BCG-PSN and thymopeptides. Meanwhile, CD4+/CD8+ ratio was also calculated. The results showed that both BCG-PSN and thymopeptides could decrease the proportion of CD4+ CD8+ T-lymphocyte subsets in the thymus, at the same time increase CD4+ T-lymphocyte, CD8+ T-lymphocyte proportion in the three tissues. The fluctuation in amplitude was greater in thymopeptides group than that in BCG-PSN group. It is concluded that acting location of thymopeptides is in thymus, its stimulating action is stronger than that of BCG-PSN, while BCG-PSN not only accelerates the differentiation in thymus, but also has some direct stimulation to peripheral CD4+ T-lymphocytes, and can maintain CD4+/CD8+ ratio within normal range. So, BCG-PSN is safer.
Adjuvants, Immunologic/*pharmacology ; Immunocompromised Host ; Mycobacterium bovis/*chemistry ; Nucleic Acids/pharmacology ; Peptide Fragments/*pharmacology ; Polysaccharides, Bacterial/*pharmacology ; T-Lymphocyte Subsets/*drug effects ; Thymus Gland/chemistry

In order to study the susceptibility of murine vaginal mucosa to Candida albicans under different conditions, vaginal lavage fluid and vaginal tissue of mice were observed and compared between murine models with normal immune system (estrogen-treated mice) and immunosuppressed murine model, and between primary infection model of vaginal candidiasis and secondary infection one. The average level of colony forming unit (CFU) from the immuosuppressed group was higher than that from estrogen-treated group at each time point and the peak time was delayed. The differences between the two groups were statistically significant (P < 0.05) from the fourth day after inoculation. A significant difference existed in the average level of CFU between the control group and the estrogen-treated group (P < 0.05), and between the control group and the immuosuppressed group (P < 0.01). It was concluded that the vaginal mucosa from the immunosuppressed mice is more susceptible to Candida albicans and no difference is found in susceptibility between mice with primary infection and secondary infection.
Candida albicans/drug effects ; Candidiasis, Vulvovaginal/*etiology ; Candidiasis, Vulvovaginal/*immunology ; Disease Susceptibility ; Estrogens/*pharmacology ; Immunocompromised Host ; Mice, Inbred ICR ; Random Allocation ; Vagina/microbiology

PURPOSE: Posaconazole is a second-generation triazole with a broad spectrum. However, there is a lack of data to support a significant role for posaconazole in the treatment of invasive fungal infection (IFI), especially in Korea. Until recently, posaconazole was available only through the Korean Orphan Drug Center. This study was designed to review the use of posaconazole at a single-center in Korea. MATERIALS AND METHODS: Data from patients who received posaconazole treatment at Catholic Blood and Marrow Transplantation Center were retrospectively reviewed between January 2007 and September 2012. RESULTS: A total of 11 cases (3 males and 8 females, median age 52 years) received posaconazole. Five patients were given the drug for mucormycosis, two for invasive aspergillosis, and four for unspecified IFI for which galactomannan (GM) assays were negative. The treatment duration ranged from 4-250 days. Three patients received posaconazole for management refractory IFI, two for intolerance of previous antifungal therapy, and six for long-term maintenance treatment. The overall successful response rate to posaconazole was 55% (six of eleven patients). Five of eleven patients died during the study period. However, only one death was attributed to the progression of IFI. None of the patients discontinued posaconazole therapy due to adverse events. CONCLUSION: Posaconazole is an attractive oral antifungal agent for salvage treatment of IFI, particularly upon diagnosis of mucormycosis or in cases in which mucormycosis cannot be ruled out due to a negative GM.
Adult ; Aged ; Antifungal Agents/adverse effects/*therapeutic use ; Female ; Humans ; Immunocompromised Host ; Male ; Middle Aged ; Mucormycosis/drug therapy ; Mycoses/*drug therapy ; Republic of Korea ; Salvage Therapy/adverse effects ; Triazoles/adverse effects/*therapeutic use

In order to study the modulatory effects of compound polysaccharide Erweikang on the immune function of the immunosuppressive mice, the positive immune modulation of Erweikang at different doses and different time points was compared when normal saline and cyclophosphamide served as controls. The results showed that different doses of Erweikang could effectively reverse the decreased induction levels of NK, IL-2, gamma-IFN and the contents of TNF and IgF of the immunosuppressive mice after administration of Erweikang for 7 to 14 days. It was suggested that compound polysaccharide Erweikang presents positive immune modulation in dose- and time-dependent manners.
Adjuvants, Immunologic ; pharmacology ; Animals ; Cyclophosphamide ; Drugs, Chinese Herbal ; chemistry ; pharmacology ; Female ; Immunocompromised Host ; immunology ; Interferon-gamma ; drug effects ; immunology ; Interleukin-2 ; immunology ; Killer Cells, Natural ; drug effects ; immunology ; Male ; Mice ; Polysaccharides ; pharmacology ; Random Allocation

PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9+/-3.3 months in the comorbidity group and 9.3+/-3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients.
Age Factors ; Aged ; Aged, 80 and over ; Antitubercular Agents/adverse effects/*therapeutic use ; Comorbidity ; Female ; Humans ; *Immunocompromised Host ; Isoniazid/adverse effects/*therapeutic use ; Male ; Retrospective Studies ; Rifampin/adverse effects/*therapeutic use ; Risk Factors ; Treatment Outcome ; Tuberculosis/*drug therapy/epidemiology/immunology